Literature DB >> 10980825

Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis.

P M Ridker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10980825     DOI： 10.1007/s11886-999-0064-2

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


× No keyword cloud information.
  13 in total

1.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.

Authors:  S R Poort; F R Rosendaal; P H Reitsma; R M Bertina
Journal:  Blood       Date:  1996-11-15       Impact factor: 22.113

2.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; S Granqvist; M Holmström; A Carlsson; P Lindmarker; P Nicol; S G Eklund; S Nordlander; G Lärfars; B Leijd; O Linder; E Loogna
Journal:  N Engl J Med       Date:  1997-02-06       Impact factor: 91.245

3.  The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).

Authors:  P Simioni; P Prandoni; A W Lensing; A Scudeller; C Sardella; M H Prins; S Villalta; F Dazzi; A Girolami
Journal:  N Engl J Med       Date:  1997-02-06       Impact factor: 91.245

4.  Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism.

Authors:  P M Ridker; C H Hennekens; J Selhub; J P Miletich; M R Malinow; M J Stampfer
Journal:  Circulation       Date:  1997-04-01       Impact factor: 29.690

5.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

6.  G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men.

Authors:  P M Ridker; C H Hennekens; J P Miletich
Journal:  Circulation       Date:  1999-03-02       Impact factor: 29.690

Review 7.  Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.

Authors:  D T Price; P M Ridker
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

8.  Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society.

Authors: 
Journal:  Lancet       Date:  1992-10-10       Impact factor: 79.321

Review 9.  Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial.

Authors:  P M Ridker
Journal:  Vasc Med       Date:  1998       Impact factor: 3.239

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321
View more
  1 in total

1.  Large-scale meta-analysis of genetic studies in ischemic stroke: Five genes involving 152,797 individuals.

Authors:  Khalil Hamzi; Amal Tazzite; Sellama Nadifi
Journal:  Indian J Hum Genet       Date:  2011-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.